HEC Pharm (China)

Guangdong HEC Pharm Co., Ltd. (东阳光药) is a comprehensive pharmaceutical company established in 2003 that engages in the research, development, production and commercialization of drugs, focusing on innovative drugs while also covering improved new drugs, generics and biosimilars. The company states it has built an independent R&D platform, internationally standard production facilities and a comprehensive sales network, and strategically focuses on the infection, chronic disease and oncology therapeutic areas. As of June 2025, it reports 150 approved drugs globally (including China, the United States and Europe) and more than 100 drugs under development, including 49 Class 1 innovative drugs in China. It also states it has applied AI technology across stages of drug R&D. In 2025, HEC Pharm (06887.HK) absorbed and merged with Dongyangguang Changjiang Pharmaceutical and listed on the Main Board of the Hong Kong Stock Exchange.

Guangdong HEC Pharm Co., Ltd. was established in 2003 as a comprehensive pharmaceutical company engaged in drug R&D, production and commercialization, focusing on innovative drugs while also covering improved new drugs, generics and biosimilars. Over more than two decades it states it has built an independent R&D platform, internationally standard production facilities and a comprehensive sales network, with strategic focus on infection, chronic disease and oncology. Its HEC Pharm Research Institute was founded in 2005. In September 2015, the Ministry of Science and Technology approved the construction of the enterprise State Key Laboratory 'State Key Laboratory for Anti-infective Drug R&D'; the laboratory was reorganized and upgraded in 2023 and formally approved in 2024 as the 'National Key Laboratory for Anti-infective Drug R&D', with Guangdong HEC Pharm Co., Ltd. as the first supporting unit. In 2023 the company was restructured into a joint-stock company. In 2025, HEC Pharm (06887.HK) absorbed and merged with Dongyangguang Changjiang Pharmaceutical and was officially listed on the Main Board of the Hong Kong Stock Exchange.

A vertically integrated pharmaceutical company driven by the dual engines of innovation and internationalization, supported by strong commercialization capabilities.

• Kewei® Oseltamivir Phosphate Granules

  For treatment of influenza A and B in adults and children aged 1 year and above; patients should use within 48 hours of first symptoms.

• Kewei® Oseltamivir Phosphate Capsules

  For treatment of influenza A and B in adults and children aged 1 year and above; patients should use within 48 hours of first symptoms.

• Dongweien® Imidafenacin Phosphate Capsules

  Must be combined with sofosbuvir tablets for treatment of chronic hepatitis C genotype 1 in non-cirrhotic adults; must not be used as monotherapy.

• Yibigan® Insulin Glargine Injection

  For adults with type 1 and type 2 diabetes requiring insulin treatment, and adolescents and children aged 6 years and above with type 1 diabetes.

• Dongweizhuo® Naphthyridine Phosphate Capsules

  Specification: 0.1g (calculated as C51H58N8O7).

• Dongyinghe® Icosabutate Phosphate Tablets

  Specification: 0.3g.

• Yibilin® Human Insulin Injection

  Specification: 3ml:300 units (pen cartridge).

• Yibilin 30® Protamine Human Insulin Mixed Injection (30R)

  Specification: 3ml:300 units (pen cartridge).

• Ertongshu® Benzbromarone Tablets

  Specifications: 25mg, 50mg.

• Oumeining® Telmisartan Tablets

  Specifications: 40mg, 80mg.

• Unconfirmed

  Reported2026.08.19

  XtalPi and Dongyangguang Pharmaceutical sign strategic cooperation to form joint venture[6]晶泰控股与东阳光药签署战略合作协议并拟成立合资公司prnasia.com

  XtalPi Holdings signed a strategic cooperation agreement with Dongyangguang Pharmaceutical; the two parties plan to establish a joint venture company and jointly build an AI plus robotics joint laboratory and a non-clinical drug large model, carrying out cooperation on underlying technology, new drug pipeline development and commercialization. Dongyangguang Pharmaceutical is expected to invest several hundred million yuan, with the two companies aiming to build an industry-leading AI drug R&D engine and achieve technology going global.

• 2020.08.18

  Reported2020.08.19

  Dongyangguang Pharma receives Hong Kong listing approval for H shares[7]东阳光药获得 H 股在香港上市批准finance.sina.com.cn

  Dongyangguang Pharma received approval from the Hong Kong Stock Exchange on August 18 for 226,200,000 H shares to be listed and traded. The related share conversion and listing procedures were not yet complete.

• Unconfirmed

  Reported2020.01.03

  China Resources Pharmaceutical Commercial and Dongyangguang Pharmaceutical sign strategic cooperation agreements[8]华润医药商业与东阳光药签署战略合作协议finance.sina.com.cn

  China Resources Pharmaceutical Commercial and Dongyangguang Pharmaceutical signed strategic and e-commerce strategic cooperation agreements recently. The cooperation is intended to provide medicine services to medicine terminals and patients nationwide through the internet.

• 2019.12.27

  Reported2019.12.27

  Dongyangguang adjusts proposed drug-rights acquisition price[9]东阳光下调拟收购药品权益交易价格finance.sina.com.cn

  Dongyangguang announced that its subsidiary Dongyangguang Pharmaceutical had adjusted the proposed acquisition price for the China rights to two diabetes drugs from RMB 2.057 billion to RMB 1.6456 billion.

• 2019.11.22

  Reported2019.11.22

  Dongyangguang Pharmaceutical proposes acquiring two diabetes drugs[10]东阳光药拟收购两款降糖药finance.sina.com.cn

  Dongyangguang Pharmaceutical proposed acquiring the rights to two diabetes drugs, jiaoguangsu ronggeliejing and liraglutide, for 2.057 billion yuan to expand its product pipeline.

Read more

1. 1广东东阳光药业股份有限公司hecpharm.com
2. 2关于东阳光药 - 广东东阳光药官网hecpharm.com
3. 3产品 - 广东东阳光药官网hecpharm.com
4. 4公司新闻 - 广东东阳光药官网hecpharm.com
5. 5HEC Pharm (China)wikidata.org
6. 6晶泰控股与东阳光药签署战略合作协议并拟成立合资公司prnasia.com
7. 7东阳光药获得 H 股在香港上市批准finance.sina.com.cn
8. 8华润医药商业与东阳光药签署战略合作协议finance.sina.com.cn
9. 9东阳光下调拟收购药品权益交易价格finance.sina.com.cn
10. 10东阳光药拟收购两款降糖药finance.sina.com.cn